Belotecan (CKD-602) in Recurrent or Progressive Carcinoma of Uterine Cervix
Completed
Sokbom Kang
Phase 2
-list item one, The purpose of this study is to evaluate the overall response rate of
belotecan (CKD-602) in recurrent or progressive carcinoma of uterine cervix
Belotecan and Cisplatin in Treating Patients With Previously Untreated, Extensive-Stage Small Cell Lung Cancer
Completed
Yonsei University
Phase 2
RATIONALE: Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the
growth of tumor cells, either by killing the cells or by stopping them from dividing.
Belotecan may stop the growth of tumor cells by blocking some of the enzymes needed for cell
growth. Giving belotecan together with cisplatin may kill more tumor cells.
PURPOSE: This phase II trial is studying how well belotecan works when given together with
cisplatin in treating patients with previously untreated extensive stage small cell lung
cancer.
Trial of Belotecan/Cisplatin in Chemotherapy Naive Small Cell Lung Cancer Patient
Completed
Chong Kun Dang Pharmaceutical
Phase 3
Belotecan (Camtobell, CKD-602, Chong Kun Dang Pharm., Korea) is a new camptothecin
derivative, that exhibits anticancer effects by inhibiting topoisomerase I. The investigators
will have a randomized prospective multicenter trial of Belotecan/Cisplatin versus
Etoposide/Cisplatin in patients with previously untreated, extensive-stage small cell lung
cancer.
Primary endpoints
- to assess Response Rate
Secondary endpoints
- to assess Overall response duration, Time to progression, Overall survival
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
